Full Press Release Details
BOSTON, July 29, 2024 (GLOBE NEWSWIRE) -- Block & Leviton announces that a securities fraud lawsuit has been filed against MacroGenics, Inc. (NASDAQ: MGNX) and certain of its executives. Investors who have lost money in their MacroGenics investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/mgnx.
What is this all about?
The lawsuit alleges that MacroGenics and its executives made material misrepresentations about the safety data from its TAMARACK Phase 2 study of vobramitamab duocarmazine. On May 9, 2024, MacroGenics revealed that the drug was significantly more dangerous than previously represented, leading to a 77% decline in MacroGenics’ stock price.
Anyone who purchased MacroGenics common stock between March 7, 2024, and May 9, 2024, and has seen their shares fall may be eligible, whether or not they have sold their investment. Investors should contact Block & Leviton to learn more.
What should you do next?
The deadline to seek appointment as lead plaintiff is September 24, 2024. A class has not yet been certified, and until a certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. If you've lost money on your investment, you should contact Block & Leviton to learn more via our case website, by email at shareholders@blockleviton.com, or by phone at (888) 256-2510.
If you have non-public information about MacroGenics, you should consider assisting in our investigation or working with our attorneys to file a report with the Securities Exchange Commission under their whistleblower program. Whistleblowers who provide original information to the SEC may receive rewards of up to 30% of any successful recovery. For more information, contact Block & Leviton at whistleblowers@blockleviton.com or by phone at (888) 256-2510.
Why should you contact Block & Leviton?
Block & Leviton is widely regarded as one of the leading securities class action firms in the country. Our attorneys have recovered billions of dollars for defrauded investors and are dedicated to obtaining significant recoveries on behalf of our clients through active litigation in the federal courts across the country. Many of the nation's top institutional investors hire us to represent their interests. You can learn more about us at our website, www.blockleviton.com, call (888) 256-2510 or email shareholders@blockleviton.com with any questions.
This notice may constitute attorney advertising.
260 Franklin St., Suite 1860
Phone: (888) 256-2510
Tags
vobramitamab duocarmazine
class action lawsuit